Breaking News, Collaborations & Alliances

Reckitt Benckiser, AntiOp in Opioid Overdose Development Pact

To employ AntiOp’s nasal drug delivery expertise

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Reckitt Benckiser Pharmaceuticals has entered into a definitive agreement with AntiOp, Inc. to co-develop a naloxone nasal spray for the reversal of opioid overdose, with the option to acquire all rights to the product upon regulatory approval. The product has the potential to be the first of its kind to treat overdose from opioid prescription painkillers and heroin.   The current standard medical protocol for treating opioid overdose is to administer an injectable form of naloxone.This product ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters